Harmonization of cancer and noncancer risk assessment: proceedings of a consensus-building workshop.
Significant advancements have been made toward the use of all relevant scientific information in health risk assessments. This principle has been set forth in risk-assessment guidance documents of international agencies including those of the World Health Organization's International Programme on Chemical Safety, the U.S. Environmental Protection Agency, and Health Canada. Improving the scientific basis of risk assessment is a leading strategic goal of the Society of Toxicology. In recent years, there has been a plethora of mechanistic research on modes of chemical toxicity that establishes mechanistic links between noncancer responses to toxic agents and subsequent overt manifestations of toxicity such as cancer. The research suggests that differences in approaches to assessing risk of cancer and noncancer toxicity need to be resolved and a common broad paradigm for dose-response assessments developed for all toxicity endpoints. In November 1999, a workshop entitled "Harmonization of Cancer and Noncancer Risk Assessment" was held to discuss the most critical issues involved in developing a more consistent and unified approach to risk assessment for all endpoints. Invited participants from government, industry, and academia discussed focus questions in the areas of mode of action as the basis for harmonization, common levels of adverse effect across toxicities for use in dose-response assessments, and scaling and uncertainty factors. This report summarizes the results of those discussions. There was broad agreement, albeit not unanimous, that current science supports the development of a harmonized set of principles that guide risk assessments for all toxic endpoints. There was an acceptance among the participants that understanding the mode of action of a chemical is ultimately critical for nondefault risk assessments, that common modes of action for different toxicities can be defined, and that our approach to assessing toxicity should be biologically consistent.
Bogdanffy
M S
MS
DuPont Haskell Laboratory for Toxicology and Industrial Medicine, P. O. Box 50, Newark, Delaware 19714, USA. matthew.s.bogdanffy@usa.dupont.com
Daston
G
G
Faustman
E M
EM
Kimmel
C A
CA
Kimmel
G L
GL
Seed
J
J
Vu
V
V
D000818:Animals; D003657:Decision Making; D004305:Dose-Response Relationship, Drug; D005544:Forecasting; D015386:Hazardous Substances / Q000494:pharmacology* / Q000633:toxicity*; D006801:Humans; D009369:Neoplasms / Q000139:chemically induced*; D017410:Practice Guidelines as Topic / Q000592:standards*; D018570:Risk Assessment; D012307:Risk Factors; D013045:Species Specificity; D014481:United States; D014484:United States Environmental Protection Agency / Q000592:standards*; D014944:World Health Organization
D015386:Hazardous Substances